Viking's VK2735 maintains weight loss with monthly dosing in trial

MarketWatch · 3 hours ago

Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that competes with Eli Lilly's Zepbound.
The clinical trial showed the drug helped people maintain weight loss even when taken once a month.
Viking Therapeutics' stock is soaring on the trial result.

Quotes

“Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound.”— MarketWatch

“Its stock is soaring.”— MarketWatch

Sources

This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a monthMarketWatch